Median (IQR) ABR among subjects with target joints at the start point of B-LONG (subanalysis 3)
| . | Prestudy treatment regimen . | |||||
|---|---|---|---|---|---|---|
| Prophylaxis∗ . | On-demand . | |||||
| Treatment regimen in B-LONG or B-YOND† . | ||||||
| WP (n = 13) . | Modified prophylaxis (n = 6) . | WP (n = 26) . | Individualized IP (n = 11) . | Modified prophylaxis (n = 5) . | On-demand (n = 14) . | |
| Prestudy ABR | 6.0 (2.0-15.0)‡ | 8.0 (5.0-20.0) | 23.0 (12.0-36.0)§ | 25.0 (22.0-36.0) | 23.0 (22.0-29.0) | 24.0 (16.0-36.0) |
| On-study ABR, overall | 3.4 (1.3-5.9) | 3.9 (3.2-6.4) | 3.1 (1.1-5.2) | 3.7 (1.0-5.1) | 2.3 (0.0-3.9) | 22.7 (14.2-26.9) |
| On-study ABR, joint | 2.2 (1.0-3.7) | 1.5 (0.9-3.2) | 1.1 (0.4-4.4) | 3.4 (0.8-3.9) | 0.6 (0.0-2.2) | 15.7 (8.2-23.3) |
| On-study ABR, pre-existing target joint‖ | 1.1 (0.0-3.7) | 1.5 (0.5-3.2) | 0.5 (0.0-1.3) | 2.3 (0.8-3.6) | 0.0 (0.0-0.0) | 15.1 (2.6-23.0) |
| On-study ABR, pre-existing target joint spontaneous bleed | 0.4 (0.0-3.2) | 0.3 (0.0-2.2) | 0.3 (0.0-1.1) | 0.9 (0.0-1.9) | 0.0 (0.0-0.0) | 7.9 (1.2-19.8) |
| . | Prestudy treatment regimen . | |||||
|---|---|---|---|---|---|---|
| Prophylaxis∗ . | On-demand . | |||||
| Treatment regimen in B-LONG or B-YOND† . | ||||||
| WP (n = 13) . | Modified prophylaxis (n = 6) . | WP (n = 26) . | Individualized IP (n = 11) . | Modified prophylaxis (n = 5) . | On-demand (n = 14) . | |
| Prestudy ABR | 6.0 (2.0-15.0)‡ | 8.0 (5.0-20.0) | 23.0 (12.0-36.0)§ | 25.0 (22.0-36.0) | 23.0 (22.0-29.0) | 24.0 (16.0-36.0) |
| On-study ABR, overall | 3.4 (1.3-5.9) | 3.9 (3.2-6.4) | 3.1 (1.1-5.2) | 3.7 (1.0-5.1) | 2.3 (0.0-3.9) | 22.7 (14.2-26.9) |
| On-study ABR, joint | 2.2 (1.0-3.7) | 1.5 (0.9-3.2) | 1.1 (0.4-4.4) | 3.4 (0.8-3.9) | 0.6 (0.0-2.2) | 15.7 (8.2-23.3) |
| On-study ABR, pre-existing target joint‖ | 1.1 (0.0-3.7) | 1.5 (0.5-3.2) | 0.5 (0.0-1.3) | 2.3 (0.8-3.6) | 0.0 (0.0-0.0) | 15.1 (2.6-23.0) |
| On-study ABR, pre-existing target joint spontaneous bleed | 0.4 (0.0-3.2) | 0.3 (0.0-2.2) | 0.3 (0.0-1.1) | 0.9 (0.0-1.9) | 0.0 (0.0-0.0) | 7.9 (1.2-19.8) |
All data are median (IQR).
For subjects receiving prestudy prophylaxis and on-study individualized prophylaxis (n = 2), ABRs for prestudy, on-study overall, on-study joint, on-study pre-existing target joint, and on-study pre-existing target joint spontaneous bleed were 5.0 (n = 1), 5.7 and 8.6, 5.7 and 7.8, 4.6 and 7.0, and 4.6 and 5.4, respectively.
Subjects are included in each treatment regimen they participated in for the duration of time on that regimen and, as such, may appear in ≥1 treatment regimen.
n = 11.
n = 25.
A bleeding episode was considered to involve a target joint if any of the bleeding joints was a target joint identified at the entry into the parent study.